Tepezza Hearing Loss Lawsuit

Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker's failure to warn about the risk. Learn more about the latest Tepezza lawsuit updates and settlement criteria here.

  • Tepezza is an infusion drug introduced in January 2020, for treatment of thyroid eye disease (TED) and Grave's disease
  • Studies and case reports link side effects of Tepezza and hearing problems
  • Tepezza lawsuits seek settlement benefits for individuals diagnosed with hearing loss or tinnitus
  • Lawyers are actively investigating and filing hearing loss claims nationwide

Tepezza Lawsuit Overview

Tepezza is an injection used to treat individuals with thyroid eye disease (TED) caused by hyperthyroidism and Grave’s disease. With no other available treatment on the market for the conditions, Tepezza was fast tracked through the FDA approval process in January 2020, without extensive research from large clinical trial groups to determine all of the potential side effects and their severity among diverse groups.

Since the drug’s release, individuals have reported suffering hearing problems after Tepezza infusions, including ringing of the ears, autophony, a sensation that their ears were plugged, or total hearing loss.

As a result of the growing evidence establishing that the drug makers knew or should have known about the risk of permanent hearing loss after infusions, individuals are now pursuing settlement benefits through a Tepezza lawsuit, alleging that permanent hearing damage could have been avoided if adequate warnings had been provided to users, regulators and the medical community.

Who is Eligible for a Tepezza Hearing Loss Lawsuit?

Financial benefits may be available through a Tepezza settlement or lawsuit payout for individuals who meet the following criteria:

  • Received multiple Tepezza infusions
  • Diagnosed with permanent or partial hearing loss, and/or
  • Diagnosed with Tinnitus (ringing of the ears)

Free Consultation With a Tepezza Lawyer

Side effects of Tepezza may cause permanent hearing problems. Lawsuits are being pursued over the drug maker's failure to warn about the risk. Find out if qualify for a settlement.

Review A Case

Related Stories

Latest 2022 Tepezza Lawsuit Updates

August 2022: The first Tepezza hearing loss lawsuit was filed over the manufacturer’s failure to disclose known hearing loss side effects from Tepezza infusions. Over the coming months, it is expected that several hundred similar lawsuits will be filed as individuals learn about the link between Tepezza and hearing loss.

May 2021: The Journal of the Endocrine Society published the findings of a study which indicate as many as 65% of Tepezza users experience new hearing loss side effects following infusion treatments to treat thyroid eye disease (TED) and Grave’s disease.

How Does Tepezza Cause Hearing Loss?

Tepezza is an insulin-like growth factor 1 receptor (IGF-IR) inhibitor medication, and it is well known that IGF-I is crucial to protecting the inner ear hair cells from noise-induced hearing damage, ischemia and medication toxicity. Therefore, it is believed that the mechanism by which Tepezza causes hearing loss is a result of the drug inhibiting the insulin-like growth factor-1 and the insulin-like growth factor-1 receptor pathway.

The manufacturer has yet to fully characterize how Tepezza works to treat Thyroid Eye Disease. Tepezza warning label further state that no formal studies evaluating the drug’s molecular, biochemical, and physiologic effects or actions have been conducted.

Multiple case reports and studies have identified instances where individuals experienced hearing loss after Tepezza infusions, often resulting in permanent hearing problems that require a hearing aid, and interfere with an individual’s ability to work or engage in normal daily activities they used to enjoy.

How Long Does Tepezza Hearing Loss Last?

Reports involving individuals who suffered hearing loss from Tepezza have shown some patients hearing problems lessen or disappear within several months of stopping the infusions. However, not all.

The permanency of hearing loss from Tepezza is still largely unknown at this time due to the novelty of the drug, and the lack of clinical data provided by the manufacturer to determine duration of side effects, or the percentage of individuals who will be left with life-long hearing loss.

According to a review published in August 2022, which examined the link between Tepezza and hearing problems after four injections, researchers report that about one third of patients who experienced hearing loss continued to experience side effects months after the last infusion.

Studies Linking Tepezza to Hearing Loss

Tepezza’s link to hearing problems was seen by the manufacturer in the early stages of the drug’s development, with two separate clinical studies finding that about 10% of users experienced hearing loss or other hearing-related problems.

Since the clinical trials, several peer reviewed medical journals have published studies and articles warning about the risk of hearing loss from Tepezza. Some of the studies and evidence suggesting that side effects of Tepezza cause hearing loss include:

May 2021Tepezza Increases Hearing Problem Risks by 65%: A study by Stanford University researchers was published in the Journal of the Endocrine Society, finding 65% of patients who took Tepezza reported hearing problems, such as ringing of the ears, autophony, a sensation that their ears were plugged, or total hearing loss.

Researchers evaluated the side effects of Tepezza in 26 patients who were given at least four infusions. Of those, 17 patients, or 65%, reported developing hearing problems. Of those, six, or 23%, reported suffering hearing loss; seven, or 27% developed tinnitus, a ringing in the ears; and three, or 12%, reported feeling an ear plugging sensation. In addition, 29% said they developed autophony, where their own voices sounded unusually loud to themselves.

The researchers recommended doctors to caution patients about the potential hearing issues they may experience after receiving Tepezza infusions and further recommended that patients be screened for hearing issues and receive baseline audiogram testing.

February 2022Tepezza Post-Marketing Safety Analysis: Prior to receiving FDA Orphan Drug designation, Horizon Pharmaceuticals conducted two clinical trials, which involved less than 100 patients.

In Horizon’s own clinical trials, the manufacturer reported that 10% of individuals treated with Tepezza suffered new hearing problems that included deafness, eustachian tube dysfunction, hyperacusis, hypoacusis, and autophony, which is the perception that your voice is too loud or echoing in your ears.

Horizon reported to the FDA that the hearing loss side effects of Tepezza were only temporary, claiming they would resolve after months of stopping infusion treatments. However, published case studies have found the contrary, documenting hearing loss injuries remaining for more than four months after stopping Tepezza infusions.

Share Your Story

If you or a loved one suffered hearing problems from Tepezza, share your experiences with the AboutLawsuits.com community and submit information for a lawyer to review whether Tepezza settlement benefits may be available.

Add Comments

Is there a Tepezza Class Action Lawsuit?

Not yet. The litigation remains in the early stages with the first Tepezza lawsuits filed in mid-2022, by individuals who were treated with the fast-tracked thyroid eye disease and developed undisclosed hearing loss injuries.

As additional lawsuits are filed against Horizon Pharmaceuticals, the manufacturer of Tepezza, a motion could be made to the U.S. Judicial Panel of Multidistrict Litigation (JPML) requesting the cases to be consolidated and centralized before one U.S. District Court Judge for common discovery and management in a manner similar to a Tepezza class action lawsuit. However, each claim would remain an individual lawsuit.

It is common in large product liability lawsuits alleging similar injuries caused by a common problem to be centralized into a multidistrict litigation to avoid duplicate discovery and conflicting rulings. If the cases are centralized for coordinated pretrial proceedings, the assigned Judge would be tasked with selecting a small group of representative claims involving similar allegations to be prepared for early trial dates, to help gauge how juries are likely to respond to certain evidence and testimony.

Following the outcomes of any potential future Tepezza bellwether trials, if settlements are not reached by manufacturers and plaintiffs, each individual case would later be remanded to U.S. District Courts nationwide for separate trial dates to determine the amount of each Tepezza lawsuit payout.

Examples of Tepezza Lawsuits and Case Reports

The amount of lawsuits over hearing loss from Tepezza are expected to grow significantly in the coming months and years as individuals learn about the emerging medical evidence linking the drug to hearing problems.

Tapezza Hearing Loss Lawsuit: The first Tepezza hearing loss lawsuit was filed by Daniel Weibel in the U.S. District Court for the Northern District of Illinois in August 2022, indicating he developed permanent hearing loss after receiving intravenous Tepezza infusions from June 2020 through September 2020 for the treatment of thyroid eye disease.

Weibel raises allegations that Horizon Pharmaceuticals misrepresented the Tepezza hearing problems recorded in its clinical trials as temporary or of a limited duration. The lawsuit claims the manufacturer failed to adequately research the permanency of many hearing loss reports recorded during its clinical trials, and failed to warn users or regulators that Tepezza can cause serious and irreversible hearing loss and/or tinnitus.

The lawsuit presents claims of failure to warn, design defect, negligent failure to warn, and negligent design. Weibel seeks both compensatory and punitive damages.

Permanent Hearing Loss After Tepezza Use Case Study: A report published in The Annals of Otology, Rhinology, and Laryngology identified an instance of a 61 year old female with Grave’s disease who suffered significant hearing loss following Tepezza treatments.

The case report indicates the Grave’s disease patient suffered bilateral hearing loss, sound distortion, and tinnitus (ringing of the ears) following treatment with teprotumumab (Tepezza). The patient’s Tepezza treatment was stopped and she was treated with oral corticosteroids. However, after 4 months post Tepezza infusion, her hearing loss symptoms remained unchanged. Researchers stated “This is one of the first descriptive cases of ototoxicity resulting in irreversible sensorineural hearing loss in the setting of treatment with teprotumumab.”

Tepezza Hearing Loss Case Report: A case report study published in the medical journal Ophthalmic Plastic and Reconstructive Surgery evaluated four cases of patients receiving Tepezza infusions and experiencing significant hearing loss side effects.
The case report warned that Teprotumumab (Tepezza) may cause a variety of irreversible hearing loss symptoms that can range from mild to severe. Specifically, researchers stated the cause of the hearing loss from Tepezza was likely due to the inhibition of the insulin-like growth factor-1 and the insulin-like growth factor-1 receptor pathway.

Authors of the case report warned that the lack of a comprehensive understanding of Tepezza’s effect on hearing should be considered when prescribing treatments to patients.

What is the Average Tepezza Settlement Amount?

With the first Tepezza lawsuits being filed in late 2022, there have not yet been any settlements or Tepezza lawsuit payouts by the manufacturer, so the average settlement amount has not been determined. However, as cases go to trial or Tepezza settlements are reported, we will track the average payouts here.

It is likely that there will be a very wide range of Tepezza settlement amounts, given the different types and severity of injuries. In some cases, Tepezza users may make a full recovery from their hearing injuries after stopping infusion treatments. However, those who suffer total hearing loss or permanent Tinnitus may be offered much larger Tepezza settlement amounts.

In determining the amount of any individual Tepezza lawsuit payouts, the following are some of the common factors that will be taken into consideration when lawyers negotiate offers:

  • The extent and duration of Tepezza infusions;
  • Permanency of the hearing problems caused by Tepezza;
  • The amount of any past or future medical expenses incurred as a result of Tepezza injuries;
  • The amount of any lost wages or loss of earning capacity;
  • The effect of the Tepezza on the individual’s overall physical and mental health or well-being;
  • The pain and mental anguish suffered in the past and that may likely be suffered in the future;
  • Additional damages individuals may be entitled to receive to settle their case.

Have a Tepezza Lawyer Review Your Hearing Loss Case

It is important to obtain experienced legal representation to pursue a Tepezza hearing loss lawsuit, and make sure you receive the financial compensation you deserve.

A Tepezza lawyer will help protect your legal interests, and they provide free consultations to help determine if you or a loved one may be eligible for a settlement. There are no fees or expenses unless a recovery is obtained in your case.


If you or a loved one were diagnosed with tinnitus or hearing loss from Tepezza, lawyers provide free consultations and claim evaluations to help determine if settlement benefits may be available. There are no fees or expenses unless you win.



"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories